HealthTree Logo
search more_vert
person Sign In / Create Account
MCRI-Funded Project Update on MILs Immunotherapy for High Risk Myeloma with Dr. Ivan Borrello
MCRI-Funded Project Update on MILs Immunotherapy for High Risk Myeloma with Dr. Ivan Borrello image
HealthTree Podcast for Multiple Myeloma
event Dec 15, 2016 / 11:00AM MST

Event Description

Ivan Borrello, MD Johns Hopkins School of Medicine Interview Date: December, 2016 

The Myeloma Crowd Research Initiative is funding two immunotherapy projects. In this show we hear an update on the T-cell project being funded by the MCRI for Dr. Ivan Borrello's MILs (marrow infiltrating lymphocytes). Designed first for high risk myeloma patients, the treatment consists of a bone marrow T-cell sample being withdrawn and then grown up a hundred fold in the presence of their tumor. A few days after transplant, these tumor-specific T-cells are then given back to the patient. The MILs approach is now two years into a phase II clinical trial. Dr. Borrello gives us an update on this open clinical trial for high risk patients and shares how is also using the MILs with allogeneic transplant and other future combinations (like with checkpoint inhibitors) and in earlier settings. This immunotherapy can be used in almost 100% of patients with fewer side effects than other types of immunotherapy approaches like CAR T cells. 

multiple myeloma

Thanks to our episode sponsor

Schedule & Agenda

Dr. Ivan Borrello & Jenny Ahlstrom

Speakers & Moderators

The panelist Ivan Borrello, MD
Ivan Borrello, MD

Ivan Borrello, MD, is associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Cell Therapy and cGMP Biologics Core for the Johns Hopkins Kimmel Cancer Center. He is a member of the Hematologic Malignancies and Bone Marrow Translational Program. Dr. Borello’s clinical research interest is in developing immune based therapies for the treatment of multiple myeloma. HIs laboratory interests have focused on the development of a novel approach of adoptive T cell therapy utilizing marrow infiltrating lymphocyte (MILs) as a more tumor specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins, and he is currently exploring this approach in other diseases including non-hematologic malignancies. Dr. Borrello is also examining strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines. Dr. Borello served a fellowship at the Johns Hopkins School of Medicine, completed his residency in internal medicine at the University of Chicago Pritzker School of Medicine, and earned his medical degree from the Medical College of Virginia.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube